Evidence map›Paper›PMID 28609092›Full record

ArticleACS applied materials & interfaces2017

Redox-Responsive Polysulfide-Based Biodegradable Organosilica Nanoparticles for Delivery of Bioactive Agents.

Seyyed Pouya Hadipour Moghaddam, Jiban Saikia, Mostafa Yazdimamaghani, Hamidreza Ghandehari

Open access · greenAbstract read
In one paragraph

Article in ACS applied materials & interfaces, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Subchronic toxicity of silica nanoparticles as a function of size and porosity.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  17. Genotoxicity of amorphous silica nanoparticles: Status and prospects.Nanomedicine : nanotechnology, biology, and medicine · 2019
    Review
  18. Article
  19. Glutathione-sensitive hollow mesoporous silica nanoparticles for controlled drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Seyyed Pouya Hadipour MoghaddamUtah Center for Nanomedicine, Nano Institute of Utah, University of Utah , Salt Lake City, Utah 84112, United States.
Jiban SaikiaUtah Center for Nanomedicine, Nano Institute of Utah, University of Utah , Salt Lake City, Utah 84112, United States.
Mostafa YazdimamaghaniUtah Center for Nanomedicine, Nano Institute of Utah, University of Utah , Salt Lake City, Utah 84112, United States.
Hamidreza GhandehariUtah Center for Nanomedicine, Nano Institute of Utah, University of Utah , Salt Lake City, Utah 84112, United States.ORCID http://orcid.org/0000-0002-9333-9964
University of Utah · US

Funding

BIOLOGICAL FATE AND BIOCOMPATIBILITY OF SILICA-BASED NANOCONSTRUCTSR01ES024681 · NIEHS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Hamid Ghandehari · 2014 to 2026
$4.1M
NIEHS NIH HHS R01 ES024681
6 · The paper itself

Abstract

Design and development of silica nanoparticles (SiO

Indexed as

NanoparticlesDoxorubicinDrug CarriersDrug Delivery SystemsOxidation-ReductionPorositySilicon DioxideSulfidesDoxorubicinDrug CarrierspolysulfideSilicon DioxideSulfidesbiodegradabledrug deliveryglutathioneredox-responsivesilica nanoparticles

Identifiers

PMID28609092
PMCPMC5665166
OpenAlexW2624773262

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.